DNM1L variations are extremely rare, with only 58 documented cases worldwide. These variations can cause a range of conditions, from optic atrophy to severe motor delays, and in extreme cases, early infant mortality.
The DNM1L gene regulates mitochondrial fission. Variations in this gene can lead to fragmented mitochondria which can result in disruption of biochemical processes inside of cells. These disruptions can lead to a number of disorders including: dystonia, epilepsy, sensory neuropathy, severe muscle atrophy, optic atrophy and encephalopathy.
We are actively seeking dedicated professionals to join our efforts in advancing research on DNM1L genetic disorders:
Your expertise is crucial in helping us improve the lives of those impacted by this rare condition.
We have partnered with Perlara PBC to conduct a drug repurposing study aimed at finding effective treatments for DNM1L variations. Through this study, we are working to identify readily available compounds that can better alleviate the symptoms associated with these rare genetic disorders.
Discover the story of Oliver and Eirinn, two individuals with a rare genetic variation linked to dopamine-responsive dystonia, and learn how it has shaped their lives.
Join us in finding solutions for DNM1L genetic disorders and improving lives.